1. A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment. (19th November 2019) Authors: Reich, K.; Augustin, M.; Thaçi, D.; Pinter, A.; Leutz, A.; Henneges, C.; Schneider, E.; Schacht, A.; Dossenbach, M.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 182:Number 4(2020) Page Start: 869 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A 24‐week multicentre, randomized, open‐label, parallel‐group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate‐to‐severe plaque psoriasis naive to systemic treatment. (1st April 2020) Authors: Reich, K.; Augustin, M.; Thaçi, D.; Pinter, A.; Leutz, A.; Henneges, C.; Schneider, E.; Schacht, A.; Dossenbach, M.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 182:Number 4(2020) Page Start: 869 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. A trial to compare the biologic drug ixekizumab with two other treatments for psoraisis, fumaric acid esters and methotrexate. (1st April 2020) Authors: Reich, K.; Augustin, M.; Thaçi, D.; Pinter, A.; Leutz, A.; Henneges, C.; Schneider, E.; Schacht, A.; Dossenbach, M.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 182:Number 4(2020) Page Start: e138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. A trial to compare the biologic drug ixekizumab with two other treatments for psoraisis, fumaric acid esters and methotrexate. (31st March 2020) Authors: Reich, K.; Augustin, M.; Thaçi, D.; Pinter, A.; Leutz, A.; Henneges, C.; Schneider, E.; Schacht, A.; Dossenbach, M.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 182:Number 4(2020) Page Start: e138 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Network meta‐analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method. (15th February 2021) Authors: Mrowietz, U.; Warren, R.B.; Leonardi, C.L.; Saure, D.; Petto, H.; Hartz, S.; Dossenbach, M.; Reich, K. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 35:Number 5(2021) Page Start: 1161 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. 比较生物制剂依奇珠单抗与其他两种治疗银屑病的药物富马酸酯和甲氨蝶呤的试验. (1st April 2020) Authors: Reich, K.; Augustin, M.; Thaçi, D.; Pinter, A.; Leutz, A.; Henneges, C.; Schneider, E.; Schacht, A.; Dossenbach, M.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 182:Number 4(2020) Page Start: e148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. 比较生物制剂依奇珠单抗与其他两种治疗银屑病的药物富马酸酯和甲氨蝶呤的试验. (31st March 2020) Authors: Reich, K.; Augustin, M.; Thaçi, D.; Pinter, A.; Leutz, A.; Henneges, C.; Schneider, E.; Schacht, A.; Dossenbach, M.; Mrowietz, U. Journal: British journal of dermatology Issue: Volume 182:Number 4(2020) Page Start: e148 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗